PCM
KLRS

Penserra Capital Management’s Kalaris Therapeutics KLRS Stock Holding History

Penserra Capital Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-65
Closed -$37K – 1580
2021
Q3 		$37K Buy
65
+1
+2% +$463 ﹤0.01% 1140
2021
Q2 		$29K Hold
64
– – ﹤0.01% 1100
2021
Q1 		$34K Sell
64
-1
-2% -$840 ﹤0.01% 881
2020
Q4 		$57K Buy
+65
New +$50K ﹤0.01% 677

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Penserra Capital Management's KLRS Position: Q4 2021 in Review

Penserra Capital Management sold out of Kalaris Therapeutics (KLRS) in Q4 2021, closing a stake of 65 shares — an estimated $37K sold.

Penserra Capital Management first reported a position in KLRS in Q4 2020 and held it in 4 quarters. The position peaked at $57K in Q4 2020. 84 funds tracked by Wall St. Rank hold KLRS as of Q4 2021.

  • Penserra Capital Management reported no remaining Kalaris Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 65 Kalaris Therapeutics shares in Q4 2021, an estimated $37K.
  • Penserra Capital Management first reported a position in Kalaris Therapeutics in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Kalaris Therapeutics position peaked at $57K in Q4 2020.
  • 84 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.